End-Stage Kidney Disease

In a remote Australian Aboriginal community with high rates of kidney disease, researchers found that eGFR directly correlated with birthweight and increasingly worsening albuminuria among adults.

The FDA has told Reata Pharmaceuticals Inc. that it needs to conduct further studies to show its treatment for Alport syndrome is effective in slowing the progression of kidney disease, according to a company press release.

Dialysis-related infections become less of a risk when dialysis centers consistently improve compliance with standardized hemodialysis care practices, according to findings published in the American Journal of Kidney Disease.

Researchers found it feasible for patients with incident kidney dysfunction requiring dialysis to receive incremental-start hemodialysis with adjuvant pharmacotherapy.

An increase in alpha-globin gene copy number was associated with a greater prevalence of chronic kidney disease and incidence of end-stage kidney disease in Black Americans, according to published data.

Due to successful and durable access for hemodialysis through 5 years, percutaneous fistulas can be an alternative to surgery for access creation in patients with end-stage kidney disease, according to a speaker at ASN Kidney Week.

Researchers comparing patients on dialysis with and those without prostate cancer found the cancer increased risk for mortality and reduced the likelihood of transplant, even though transplantation improved survival by 80% for all patients.

Individuals who survived for at least 30 days after contracting COVID-19 — considered the acute phase of the illness — were at greater risk for adverse kidney outcomes, even if the infection was deemed mild, study results showed.

Incremental hemodialysis showed fewer adverse events in patients with residual kidney function compared with standard hemodialysis treatment, according to results of a pilot study.

For children and adolescents initiating dialysis, lupus nephritis conferred a higher hospitalization risk, as well as a lower likelihood of transplantation, compared with other glomerular causes of end-stage kidney disease.